Clinical trial

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention HKI-272 Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Surgical Resection Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Capecitabine Normalized identity: capecitabineView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention HKI-272 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Ado-Trastuzumab Emtansine Normalized identity: ado-trastuzumab emtansineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-02-01

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

HKI-272DRUG

Surgical ResectionPROCEDURE

CapecitabineDRUG · verified · RxNorm: capecitabine

HKI-272DRUG

Ado-Trastuzumab EmtansineDRUG · verified · RxNorm: ado-trastuzumab emtansine

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Translational Breast Cancer Research Consortiumcollaborator

Puma Biotechnology, Inc.collaborator

Mapped research locations

BostonMassachusetts, United States3 HoustonTexas, United States2 PittsburghPennsylvania, United States2 BaltimoreMaryland, United States1 San FranciscoCalifornia, United States1 DurhamNorth Carolina, United States1 Washington D.C.District of Columbia, United States1 Ann ArborMichigan, United States1 RochesterMinnesota, United States1 Chapel HillNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01494662 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.